Syngenta Group Reports Q1 2026 Sales of $6.4 Billion and EBITDA Margin Expansion to 21.9% Across All Four Business Units

Key Takeaways

• Syngenta Group reported Q1 2026 sales of $6.4 billion, up 2% year-over-year (-4% at constant exchange rates), with EBITDA rising 5% to $1.4 billion (+1% CER) and EBITDA margin expanding 0.6 percentage points to 21.9%, driven by higher-margin business, cost discipline, and operational efficiency improvements. All figures are presented on a like-for-like basis following the transfer of the Sinofert business to Sinochem Holdings on December 31, 2025.
• Syngenta Crop Protection generated Q1 2026 sales of $3.5 billion (+3%, -3% CER), with Europe up 18% on strong biologicals demand and nearly 350 product approvals in the quarter; groundbreaking ceremonies were held for new R&D sites in Shanghai and at Jealott’s Hill (UK), where the BioSTaR facility will be based.
• Syngenta Seeds delivered Q1 2026 sales of $1.5 billion (+7%, +1% CER), with LATAM surging 60% and Brazil up 26% on strong Southern Hemisphere campaign finishes; X-Terra® hybrid wheat launched in France, and Viptera Pro — a next-generation corn trait — launched in China.
• Syngenta Group China recorded sales of $1.5 billion (+1%, -4% CER), with underlying growth of 11% (+5% CER) after adjusting for the grain trading exit; Branded Formulation grew 15%, Seeds 9%, and Yangnong Chemical 13%, with WeiJing 威境® (Bisulflufen) receiving registration approval in China.
• Syngenta Group’s AI programs established in 2025 are now scaling across product development, precision agronomy, and commercial operations, reinforcing the company’s position as one of the leading adopters of AI technology in agriculture; the 2025 ESG Report was also published on April 29, 2026, under a new “Higher yields, lower impact” sustainability framework.

Syngenta Group Posts 2% Sales Growth in Q1 2026, EBITDA Rises 5%

Syngenta Group reported Q1 2026 sales of $6.4 billion, a 2% increase from $6.3 billion in Q1 2025 (-4% at constant exchange rates), with growth across all four business units despite a market environment shaped by geopolitical uncertainty and trade disruption. EBITDA rose 5% to $1.4 billion (+1% CER), and the EBITDA margin expanded approximately 0.6 percentage points to 21.9% from 21.4% in Q1 2025. The improvement reflects the Group’s focus on higher-margin, innovation-led products, disciplined cost management, and continued operational efficiency gains. All figures are presented on a like-for-like basis following the transfer of the Sinofert grain trading business to Sinochem Holdings on December 31, 2025, which is no longer consolidated as of January 2026.

Crop Protection Leads with 350 Approvals; Seeds Surges 60% in LATAM

Syngenta Crop Protection recorded Q1 2026 sales of $3.5 billion (+3%, -3% CER). Europe was the standout region, growing 18% (CER +5%) on strong biologicals demand and favorable crop conditions, including new approvals for ORONDIS® in Austria, Germany, and the Netherlands for downy mildew control. China grew 20% year-on-year on continued demand for ADEPIDYN® and TYMIRIUM® technologies. AMEA (excluding China) grew 3%. Latin America declined 16% (-3% in Brazil) due to adverse weather, pricing pressure in Mexico, and elevated channel inventories in Argentina. North America fell 12% due to a planned timing shift in channel stocking, though early customer demand for PLINAZOLIN® and TYMIRIUM® technologies was strong. The quarter included nearly 350 product approvals globally, and groundbreaking ceremonies were held for new R&D facilities in Shanghai and at Jealott’s Hill, UK (BioSTaR).

Syngenta Seeds reported Q1 2026 sales of $1.5 billion (+7%, +1% CER). LATAM surged 60% and Brazil grew 26%, supported by strong Southern Hemisphere campaign finishes and Brazil’s second corn season. AMEA grew 11%, Europe 9%, and China 8%. North America declined 3% due to planned restructuring. Key launches included X-Terra® hybrid wheat in France, Viptera Pro (next-generation corn trait) in China, and a new North American soybean combining Enlist E3® with the FG72 herbicide-tolerant event, with commercial availability anticipated in 2029. Vegetable Seeds grew 4% and Flowers 5%.

Syngenta Group China Delivers 11% Underlying Growth After Grain Trading Exit

Syngenta Group China reported Q1 2026 sales of $1.5 billion (+1%, -4% CER). Adjusting for the exit from grain trading, underlying growth reached 11% (+5% CER). Branded Formulation grew 15%, Seeds grew 9%, and Yangnong Chemical grew 13%. New products showed strong commercial traction, including ADEPIDYN® and TYMIRIUM® technologies and biological crop protection products. Yangnong Chemical received official registration approval in China for WeiJing 威境® (Bisulflufen), a novel miticide with a mode of action not previously available in the Chinese market.

ADAMA, Syngenta Group’s post-patent active ingredient business, reported Q1 2026 sales of $1.0 billion (+4%, -1% CER). North America grew 8%, EAME grew 14%, APAC (excluding China) grew 2%, Latin America declined 2%, and China fell 19% as ADAMA continued its strategic reduction of basic chemical and low-margin products. Notable Q1 launches included MARATHON® in Australia, ADAMA’s first high-load Pyrasulfotole formulation with an integrated crop safener for post-emergence weed control in wheat and barley.

AI Programs Scale Across Organization; 2025 ESG Report Published Under New Framework

Syngenta Group’s AI programs established in 2025 are now scaling across the organization, spanning product development, precision agronomy, and commercial operations. The Group stated these deployments are generating measurable business impact and position it as one of the leading adopters of AI technology among agricultural companies. On April 29, 2026, the Group also published its 2025 ESG Report under a new sustainability framework — “Higher yields, lower impact” — structured around three business imperatives to deliver outcomes for farmers, communities, and the environment. The report is available at syngentagroup.com.

Syngenta Group Q1 2026 Financial Summary